Alpine Immune Sciences (NASDAQ:ALPN) and Oragenics (NYSEAMERICAN:OGEN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.
Profitability
This table compares Alpine Immune Sciences and Oragenics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Alpine Immune Sciences | -606.16% | -80.38% | -30.76% |
Oragenics | N/A | -499.13% | -178.75% |
Earnings and Valuation
This table compares Alpine Immune Sciences and Oragenics' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Alpine Immune Sciences | $1.74 million | 177.15 | $-41,850,000.00 | ($2.28) | -5.68 |
Oragenics | N/A | N/A | $-15,570,000.00 | ($0.37) | -2.76 |
Oragenics has lower revenue, but higher earnings than Alpine Immune Sciences. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Alpine Immune Sciences and Oragenics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Alpine Immune Sciences | 0 | 0 | 6 | 0 | 3.00 |
Oragenics | 0 | 1 | 0 | 0 | 2.00 |
Alpine Immune Sciences presently has a consensus target price of $19.40, indicating a potential upside of 49.81%. Given Alpine Immune Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alpine Immune Sciences is more favorable than Oragenics.
Insider and Institutional Ownership
52.9% of Alpine Immune Sciences shares are owned by institutional investors. Comparatively, 12.8% of Oragenics shares are owned by institutional investors. 76.1% of Alpine Immune Sciences shares are owned by company insiders. Comparatively, 9.9% of Oragenics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
Alpine Immune Sciences has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.
Summary
Alpine Immune Sciences beats Oragenics on 9 of the 13 factors compared between the two stocks.